Editor-in-Chief

Philip D. Walson, MD
Georg-August-Universität Medical School
Göettingen, Germany

Section Editors, Pharmaceutical Economics & Health Policy

Alan Lyles, ScD, MPH, RPh
Division of Government and Public Administration
University of Baltimore

Judith A. Shinogle, PhD, MSc
Maryland Institute for Policy Analysis and Research
University of Maryland

Contributing Editor, Pharmaceutical Economics & Health Policy

John G. Ryan, DrPH
Family Medicine and Community Health
Miller School of Medicine, University of Miami

Editor, New Drug Reviews

Harold L. Kirschenbaum, PharmD
Arnold & Marie Schwartz College of Pharmacy and Health Sciences
Long Island University

Section Editor, Pediatric, Adolescent, & Maternal Therapeutics

Michael G. Spigarelli, MD, PhD
Cincinnati Children’s Research Foundation

Editorial Board

  • Professor Georges Akoun
    Hôpital Tenon, Paris
    Internal Medicine
  • Michael Aman, PhD
    The Nisonger Center
    The Ohio State University
    Psychology/Psychiatry
  • Xavier Badia, MD, MPH, PhD
    Catalan Institute of Public Health
    University of Barcelona
    Pharmacoeconomics and Outcomes Research
  • Kevin T. Bain, BPharm, PharmD, MPH
    excelleRx, Inc.
    Geriatric Pharmacotherapy & Hospice and Palliative Care
  • Rajesh Balkrishnan, PhD
    University of Michigan
    Pharmaceutical Outcomes Evaluation
  • Judith Barr, ScD
    Center for Outcomes Assessment
    Northeastern University
    Outcomes Research
  • Daniel K. Benjamin, Jr., MD, PhD
    Duke University
    Pediatrics
  • Seth Mark Berney, MD
    Louisiana State University Health Sciences
    Rheumatology and Clinical Immunology
  • R. Keith Campbell, BPharm, MBA
    College of Pharmacy
    Washington State University
    Pharmacology
  • Judy Cheng, PharmD, MPH, FCCP, BCPS
    Massachusetts College of Pharmacy and Health Sciences
    Cardiovascular Pharmacotherapy
  • Stephen J. Coons, PhD
    Critical Path Institute
    Patient-Reported Outcomes
  • Howard J. Eisen, MD
    Advanced Heart Failure and Transplant Center
    Temple University School of Medicine
    Cardiovascular Medicine
  • Kevin C. Farmer, PhD
    Health Sciences Center
    The University of Oklahoma
    Pharmaceutical Economics
  • Robert L. Findling, MD
    Case Western Reserve University School of Medicine
    Pediatric Psychopharmacology
  • Albert J. Finestone, MD
    Temple University School of Medicine
    Geriatrics
  • Facundo Garcia-Bournissen, MD
    Hospital for Sick Children
    Clinical Pharmacology
  • M. Eric Gershwin, MD
    University of California at Davis
    School of Medicine
    Allergy/Clinical Immunology
  • Susan Goodin, PharmD, FCCP, BCOP
    The Cancer Institute of New Jersey
    University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School
    Oncology
  • Mitchell H. Grayson, MD
    Medical College of Wisconsin
    Allergy and Immunology
  • Elliot V. Hersh, DMD, MS, PhD
    School of Dental Medicine
    University of Pennsylvania
    Clinical Pharmacology/Pain Management
  • Michael B. Kays, PharmD, FCCP
    Purdue University School of Pharmacy
    Infectious Diseases/ Pharmacokinetics & Pharmacodynamics
  • Gideon Koren, MD
    Hospital for Sick Children
    Pediatric Pharmacology
  • Denys T. Lau, PhD
    Feinberg School of Medicine
    Northwestern University
    Health Services Evaluation and Policy Research
  • David F. Lehmann, MD, PharmD
    State University of New York
    Upstate Medical Center
    Pharmacoepidemiology/Drug Metabolism
  • Steven D. Lidofsky, MD, PhD
    University of Vermont College of Medicine
    Hepatology
  • Colleen J. Metge, BPharm, PhD
    University of Manitoba
    Pharmaceutical Economics & Epidemiology
  • Michael A. Moore, MD
    Wake Forest University School of Medicine
    Nephrology/Hypertension
  • C. Daniel Mullins, PhD
    University of Maryland School of Pharmacy
    Prostate Cancer
    Health Disparities Research
  • Ciaran O’Neill, BSc, PhD
    Cairns School of Business and Economics
    National University of Ireland
    Health Economics and Policy
  • Gary M. Owens, MD
    Keystone Health Plan East
    Internal Medicine/Family Practice
  • Lawrence Charles Parish, MD
    Jefferson Medical College
    Thomas Jefferson University
    Dermatology
  • Robert S. Pinals, MD
    University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School
    Rheumatology
  • Rosemary C. Polomano, PhD, RN
    Pennsylvania State University College of Medicine
    Milton S. Hershey Medical Center
    Pain Management/Anesthesiology
  • Christian B. Ramers, MD, MPH
    University of Washington
    Infectious Diseases,
    Internal Medicine,
    Pediatrics and Global Health
  • Karen L. Rascati, BPharm, PhD
    College of Pharmacy
    The University of Texas at Austin
    Pharmaceutical Economics
  • Karel Raska, Jr., MD, PhD
    University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School
    Clinical Immunology & Immunopathology
  • Michael D. Reed, PharmD
    Akron’s Children’s Hospital
    Pediatrics
  • Martha Sajatovic, MD
    Case Western Reserve University
    Psychiatry
  • Paul J. Scheel, Jr., MD
    The Johns Hopkins University School of Medicine
    Nephrology
  • Richard M. Schulz, PhD
    College of Pharmacy
    University of South Carolina
    Outcomes Research
  • Gerald Schumacher, PharmD, PhD
    Bouve College of Pharmacy and Health Sciences
    Northeastern University
    Outcomes Research
  • David A. Sclar, BPharm, PhD
    College of Pharmacy
    Washington State University
    Pharmaceutical Economics & Health Policy
  • James W. Shaw, PhD, PharmD, MPH
    College of Pharmacy
    University of Illinois at Chicago
    Health Outcomes Assessment and Modeling
  • Tracy L. Skaer, BPharm, PharmD
    College of Pharmacy
    Washington State University
    Pediatrics/Nutrition
  • Alison Snow Jones, PhD
    School of Public Health
    Drexel University
    Health Economics
  • Burton E. Sobel, MD
    The University of Vermont
    College of Medicine
    Cardiology
  • Brian Tomlinson, MD
    Chinese University of Hong Kong
    Cardiovascular Pharmacotherapy
  • John N. van den Anker, MD, PhD
    Children’s National Medical Center
    Pediatric Pharmacology
  • Alexander Vinks, PharmD, PhD
    University of Cincinnati
    Pharmacokinetics/Pharmacodynamics
  • Benedetto Vitiello, MD
    Child & Adolescent Treatment and Preventative Intervention Research Branch
    National Institute of Mental Health
    Psychopharmacology
  • Judd L. Walson, MD, MPH
    University of Washington
    Internal Medicine/Pediatrics
  • Robert Ward, MD
    University of Utah
    Neonatology
  • John T. Wilson, MD
    Children’s Clinical Research Center
    Pediatric Pharmacology


Acknowledgments

  • Prof. Georges Akoun—No financial relationships with commercial interests.
  • Dr. Michael Aman—Grant Support: Forest Research, Bristol-Myers Squibb, Johnson & Johnson; Consultant: Forest Research, Supernus.
  • Dr. Xavier Badia—General Manager: Observational Outcomes Research Centre of Excellence at IMS Health.
  • Dr. Kevin T. Bain—No financial relationships with commercial interests.
  • Dr. Rajesh Balkrishan—Consultant: Merz Pharmaceuticals, sanofi-aventis, GlaxoSmithKline, Bristol-Myers Squibb, Takeda, Novartis AG, Roche Pharmaceuticals, Beiersdorf, Armada Healthcare, Genesis Biopharma.
  • Dr. Judith Barr—No financial relationships with commercial interests.
  • Dr. Seth Mark Berney—Clinical Research: Biogen Idec, Genentech, Medimmune, Roche; Stock Ownership: Pfizer.
  • Dr. R. Keith Campbell—No financial relationships with commercial interests.
  • Dr. Judy Cheng—No financial relationships with commercial interests.
  • Dr. Stephen J. Coons—No financial relationships with commercial interests.
  • Dr. Howard J. Eisen—Research Grants: Novartis, St. Jude Medical, Boston Scientific, Medtronic, Osiris, Scios; Consultant: Novartis, XDx, Inc., GlaxoSmithKline, Wyeth, Medtronic; Scientific Advisor: Novartis, Wyeth, XDx, Inc., Medtronic; DSMB: Actelion, St. Jude Medical.
  • Dr. Robert Findling—Research Support, Consultant, Speaker’s Bureau: Abbott, Addrenex, AstraZeneca, Biovail, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Johnson & Johnson, KemPharm Lilly, Lundbeck, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, sanofi-aventis, Sepracore, Schering-Plough, Shire, Solvay, Supernus Pharmaceuticals, Validus, Wyeth.
  • Dr. Albert J. Finestone—No financial relationships with commercial interests.
  • Dr. Facundo Garcia-Bournissen—No financial relationships with commercial interests.
  • Dr. M. Eric Gershwin—No financial relationships with commercial interests.
  • Dr. Susan Goodin—No financial relationships with commercial interests.
  • Dr. Mitchell H. Grayson—Research Grants: Genentech, NIH.
  • Dr. Elliot V. Hersh—Stock Ownership: Merck, Procter and Gamble; Advisory Board: Novalar Pharmaceuticals; Continuing Education Support: Xanodyne Pharmaceuticals; Grant Support: Wyeth (Pfizer Consumer Health Care), St. Renatus LLC.
  • Dr. Michael B. Kays—Research Grants: Ortho-McNeil, Bayer, Bristol-Myers Squibb, Abbott, Pfizer, GlaxoSmithKline; Speaker’s Bureau: Astellas, Ortho-McNeil, Merck.
  • Dr. Harold L. Kirschenbaum—No financial relationships with commercial interests.
  • Dr. Gideon Koren—Consultant: Bayer, Duchesnay, Novartis.
  • Dr. Denys T. Lau—No financial relationships with commercial interests.
  • Dr. David F. Lehmann—No financial relationships with commercial interests.
  • Dr. Steven D. Lidosky—No financial relationships with commercial interests.
  • Dr. Alan Lyles—Consultant: SMT, Inc., Management Sciences for Health.
  • Dr. Colleen J. Metge—Consultant: Bayer Inc.; Analyst: sanofi-aventis.
  • Dr. Michael A. Moore—Consultant: Daiichi-Sankyo Pharmaceuticals, Forest Laboratories, Nicox Pharmaceuticals; Speaker’s Bureau: Daiichi-Sankyo Pharmaceuticals, Forest Laboratories.
  • Dr. C. Daniel Mullins—Consultant/Honoraria: Bayer, Bristol-Myers Squibb, Cubist, Eisai, Eil Lilly, Novartis, Pfizer, sanofi-aventis; Grant Support: BMS, GSK, Novartis, Pfizer, sanofi-aventis.
  • Dr. Ciaran O’Neill—Financial Support: GlaxoSmithKline (for honoraria, travel cost, and living expenses of masters program), Pfizer (evaluation of home delivery service in 2009).
  • Dr. Gary M. Owens—Consultant: Towers Watson, Mercer, Milliman, Xcenda, Presscott Associates, Teva, Novartis, Genzyme, Asthmatyx, Auxilium, Beacon Healthcare Communications, Eli Lilly, Amgen.
  • Dr. Lawrence Charles Parish—Research Grants: Abbott, Allergan, Amgen, Astellas, Basilea, Capstone, Cipher, Eli Lilly, GlaxoSmithKline, Merz, Quinnova, Warner-Chilcott.
  • Dr. Robert S. Pinals—No financial relationships with commercial interests.
  • Dr. Rosemary C. Polomano—Speaker’s Bureau: Ortho-McNeill Pharmaceuticals, King Pharmaceuticals, Pfizer; Advisory Board: Ortho-McNeill Pharmaceuticals, Pfizer, Axcelrx; Honoraria: Ortho-McNeill Pharmaceuticals, King Pharmaceuticals, Pfizer, Axcelrx.
  • Dr. Christian Ramers—No financial relationships with commercial interests.
  • Dr. Karen Rascati—Grants: Abbot, Takeda, Shire, Pfizer.
  • Dr. John G. Ryan—No financial relationships with commercial interests.
  • Dr. Martha Sajatovic—Research Grants: GlaxoSmithKline, AstraZeneca; Consultant: GlaxoSmithKline, Cognition Group, United BioSource Corporation (UBC), ePharma Solutions; Royalties: Springer Press, Johns Hopkins University Press, Oxford Press.
  • Dr. Paul J. Scheel, Jr.—No financial relationships with commercial interests.
  • Dr. Richard M. Schultz—No financial relationships with commercial interests.
  • Dr. Gerald Schumacher—No financial relationships with commercial interests.
  • Dr. David A. Sclar—Financial Interest and/or Affiliations: 3M, Allergan, Alza, Amgen, AstraZeneca, Australia Ministry of Health, Aventis, Axcan, Baxter Bioscience, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Canada Ministry of Health, Eli Lilly and Company, Forest Laboratories, Gambro, Genzyme, GlaxoSmithKline, Johnson & Johnson, New Zealand Ministry of Health, Novartis, Pfizer, Republic of China Ministry of Health, State of Washington Department of Public Health, State of Washington Office of the Attorney General, State of Washington Office of the Insurance Commissioner, Teva, United Kingdom Ministry of Health, US Food and Drug Administration, US Health Care Financing Administration, US Presidential Task Force on Health Care Reform, US Senate Select Committee on Aging, US Veterans Administration, Warner-Lambert, World Health Organization, Wyeth.
  • Dr. James W. Shaw—No financial relationships with commercial interests.
  • Dr. Judith A. Shinogle—Grant: BIO.
  • Dr. Tracy L. Skaer—No financial relationships with commercial interests.
  • Dr. Alison Snow Jones—No financial relationships with commercial interests.
  • Dr. Burton E. Sobel—No financial relationships with commercial interests.
  • Dr. Brian Tomlinson—Research Funding: AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Merck, Merck Sharp and Dohme, Novartis, Otsuka, Pfizer, Roche, sanofi-aventis, Servier; Consultant/Speaker: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Kowa, Merck, Merck Sharp and Dohme, Novartis, Pfizer, Roche, sanofi-aventis, Schering-Plough, Servier.
  • Dr. John N. van den Anker—No financial relationships with commercial interests.
  • Dr. Alexander Vinks—No financial relationships with commercial interests.
  • Dr. Benedetto Vitiello—No financial relationships with commercial interests.
  • Dr. Judd L. Walson—No financial relationships with commercial interests.
  • Dr. Robert Ward—Consultant: Johnson & Johnson; Director of Clinical Trials: University of Utah Department of Pediatrics; Primary Investigator: Studies at the University of Utah funded by Biosynexus and Johnson & Johnson (no direct revenue received for these studies).
  • Dr. John T. Wilson—No financial relationships with commercial interests.